Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways.

ABSTRACT: Pancreatic cancer (PanCa) presents a catastrophic disease with poor overall survival at advanced stages, with immediate requirement of new and effective treatment options. Besides genetic mutations, epigenetic dysregulation of signaling pathway-associated enriched genes are considered as novel therapeutic target. Mechanisms beneath the deoxyribonucleic acid methylation and its utility in developing of epi-drugs in PanCa are under trails. Combinations of epigenetic medicines with conventional cytotoxic treatments or targeted therapy are promising options to improving the dismal response and survival rate of PanCa patients. Recent studies have identified potentially valid pathways that support the prediction that future PanCa clinical trials will include vigorous testing of epigenomic therap

SUBMITTER: Bararia A 

PROVIDER: S-EPMC10514732 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature